AnticoagEvaluator

Downloads
Revenue

Description

Make well-informed decisions on antithrombotic therapy for your non-valvular AF patients with the updated AnticoagEvaluator.
Use the app to:
• Calculate a patient's renal function and risk of ischemic stroke, thromboembolism, and bleed
• Review ACC/AHA/HRS Guideline-driven therapy guidance for stroke prevention
• Generate individualized risk for antithrombotic therapy options based on individual clinical trials.
• Improve accurate use of DOACs with adjusted dosage based on prescribing information, fine-tuned for renal and other patient characteristics.
This app is based on SPARC Tool, developed by Peter Loewen, ACPR, Pharm.D., FCSHP, which can be viewed at www.sparctool.com
Hide Show More...

Screenshots

AnticoagEvaluator FAQ

  • Is AnticoagEvaluator free?

    Yes, AnticoagEvaluator is completely free and it doesn't have any in-app purchases or subscriptions.

  • Is AnticoagEvaluator legit?

    🤔 The AnticoagEvaluator app's quality is mixed. Some users are satisfied, while others report issues. Consider reading individual reviews for more context.

    Thanks for the vote

  • How much does AnticoagEvaluator cost?

    AnticoagEvaluator is free.

  • What is AnticoagEvaluator revenue?

    To get estimated revenue of AnticoagEvaluator app and other AppStore insights you can sign up to AppTail Mobile Analytics Platform.

User Rating

5 out of 5

1 ratings in Brazil

5 star
1
4 star
0
3 star
0
2 star
0
1 star
0
Ratings History

AnticoagEvaluator Reviews

Excellent Program

Yaubs on

Brazil

Every Phisician who works with anticoagulantion should has this program on his pocket. Congratulations to the developers and to ACC for supporting this project.

Credible?

cdd853 on

United States

Results seem very one-sided. Wonder where funding came from? If results always show same anticoag, why have app?

Great app very useful

Mnickola on

United States

The ACC web team is so responsive!!! App works great now on iPhone 6

Loss of function in iOS 8

Jaa131 on

United States

Can no longer select and receive details for a particular therapy option. This needs to be fixed.

Temporary Workaround

pkilaru on

United States

It's become less functional since the IOS 8; you can no longer choose a therapy and see the details of its usefulness or the lack thereof. However, here is temporary workaround until they fix it: after selecting the risk factors for your patient, you click on the email icon and it will give you the relative risk reductions for all of the therapies. I know it's inelegant but is still functional. Hopefully, they will fix it soon.

No conversion

Travbrink on

United States

Since iOS8 update app is useless as I'm finding with a lot of apps post iOS8.

Current version fails

Cadiovention1 on

United States

Ios8 version does not work

Top of the screen

HalbeDoktor on

United States

Agree with the first review Top email and risk summary are hidden behind battery and time

Ios7 update messed up the app

AikBanda on

United States

The new update that made this app ios7 compatible actually has a bug. The bar that is supposed to seperate the app display screen from top part of the screen where time and battery are displayed is actually at the bottom of the screen. Therefore all the results hide behind time and battery icon

Great tool to estimate risk

Some dude with a bank account on

United States

Especially like how each therapy can be compared.

Store Rankings

Ranking History
App Ranking History not available yet
Category Rankings
App is not ranked yet

AnticoagEvaluator Installs

Last 30 days

AnticoagEvaluator Revenue

Last 30 days

AnticoagEvaluator Revenue and Downloads

Gain valuable insights into AnticoagEvaluator performance with our analytics.
Sign up now to access downloads, revenue, and more.
This page includes copyrighted content from third parties, shared solely for commentary and research in accordance with fair use under applicable copyright laws. All trademarks, including product, service, and company names or logos, remain the property of their respective owners. Their use here falls under nominative fair use as outlined by trademark laws and does not suggest any affiliation with or endorsement by the trademark holders.